Several studies based on clinical tumor samples also confirmed the risk of HJURP to the tumorigenesis or development of cholangiocarcinoma (Yang et al., 2022), colorectal cancer (Kang et al., 2020), pancreatic cancer (Wang et al., 2020), triple-negative breast cancer (Mao et al., 2022) and hepatocellular carcinoma (Chen et al., 2018). Here, HJURP is linked to cholangiocarcinoma.